Among the anti-cancer drugs developed in this laboratory, one was developed for the purpose of being a broad-spectrum anti-cancer drug.
The word "broad spectrum" can easily make people think of broad-spectrum antibiotics.
[Broad-spectrum antibiotics] are drugs that can kill a variety of pathogenic microorganisms, such as [penicillin], a drug with a very brilliant record.
Someone once asked on a forum, what would you get in return if you brought a ton of [penicillin] back to those war-torn days?
Um.
There will be an evaluation of [the most reliable friend].
And the treatment of watching the ceremony in Tiananmen Square.
really.
In that era, many diseases, such as tuberculosis, relied on this miracle drug.
With this magic medicine, how many lives of soldiers can be saved.
One can imagine how important this thing was in those days.
But [broad-spectrum anticancer drugs] are not [broad-spectrum antibiotics].
The so-called broad-spectrum anti-cancer means that it has an effect on multiple different types of tumor targets.
However, having an effect does not necessarily mean that it is miraculous. Some targets are more sensitive to drugs and have significant curative effects; others are not and can only control tumors from growing so fast or the condition from getting worse.
For example, [Vitrakvi], which was acceleratedly approved by the Food and Drug Administration of a certain country in 2018, is a so-called broad-spectrum anti-cancer drug.
The characteristic of this drug is that it does not take into account the area where the cancer occurs, which is why it is called "broad spectrum". Its essence is still a targeted drug. The target is TRK, and the scope of its approved use is the treatment of NTRK carriers.
Gene fusion in adult and pediatric patients with locally advanced or metastatic solid tumors.
TRK fusion is a genetic abnormality, which is the fusion of the TRK gene with other genes. This condition accounts for about 0.5% to 1% of common tumors, but it accounts for more than 90% of some rare tumors. Among them
Including salivary gland cancer, certain juvenile breast cancer, infantile fibrosarcoma, etc., TRK fusion will appear in the early stage of the tumor and persist during the growth and spread of the tumor.
The development of [Vitrakvi] focuses on this TRK. It is essentially an oral TRK inhibitor that targets specific gene mutations rather than specific cancer types.
In clinical trials, [Vitrakvi] showed an objective response rate of 75%.
What does it mean? It means that no new lesions appear, and the tumor marker test remains normal for at least 4 weeks.
Among them, the complete remission rate was 22%.
However, the clinical cure referred to in medicine requires that the disease does not relapse within 5 years.
Therefore, in terms of curative effect, this medicine is far from reaching the imaginary realm of a miracle medicine.
The specific explanation of the scope of application of [Vitrakvi] is as follows: there are no known acquired resistance mutations, metastatic disease or surgical resection may lead to serious complications, and there are no satisfactory alternative treatment options or treatment for patients with disease progression.
What it means in human terms is that if the patient has no other better treatment method, try this.
………………………………………………………………………………………………………………………………
………
No matter what anti-cancer drug, the research and development process is full of hardships.
[Xuanhu Technology] The same is true for this broad-spectrum anti-cancer drug.
Researchers are working day and night to screen PD-1 antibodies in order to find PD-1 inhibitors, humanized monoclonal antibodies that block the PD-1 receptor molecule.
The full name of PD-1 is programmed death receptor 1. When it binds to the ligand PD-L1, it will shut down the immune response of T cells. T cells will not be able to detect tumor cells and send attack signals to tumor cells. PD-1 is
The immune regulation of targets is of great significance in anti-tumor and anti-autoimmune diseases.
The mechanism of action of monoclonal antibodies against PD-1 and PD-L1 is actually that PD-1 and PD-L1 bind to each other, which can inhibit the activity of T cells, thus inhibiting the effect of killing tumors. If targeted pathway blocking is given
, can activate T cell activity and achieve anti-tumor effects.
The R&D team of [Xuanhu Technology] is very lucky.
They didn't waste much time to get results, and successfully passed the animal experiments and the first phase of clinical trials.
However, in the expanded clinical phase II experiment, the new drug developed by the R&D team of [Xuanhu Technology] has not been satisfactory in terms of overall survival rate, objective response rate, disease control rate, clinical benefit rate and response duration.
.
To be precise, the effect is very unsatisfactory.
This means that this anti-cancer drug failed in human trials.
In fact, in the research and development of anti-cancer drugs, failure is normal, and success is accidental.
This is true whether it is a world-famous large company or a small company.
Therefore, the cost of research and development of anticancer drugs is very high.
It's too easy to lose sight of it.
Many domestic pharmaceutical companies are keen on producing generic drugs, but are not keen on developing new drugs. That's it.
Because if it is not done well, the company will develop a drug and face bankruptcy.
[Xuanhu Technology] has a big boss who is very wealthy and not interested in money, but only interested in influence.
That’s why you dare to spend money like this!
Even if this research fails.
The senior management of [Xuanhu Technology] did not criticize anything harshly, but let the team have a good rest before continuing to work.
And that failed broad-spectrum anti-cancer drug was just shelved.
………………………………………………………………………………………………………………………………
…
This is the [anti-cancer drug] that Wu Siyuan requested.
He asked [Xuanhu Technology] to send relevant information to [Yuanyuan Company].
[Yuanyuan Company] There is a laboratory that He Youman is personally in charge of.
Her team took over and re-researched this [anti-cancer drug] and added certain things.
On the surface, some other small molecule compounds are added, but in fact they are filled with [nano medical particles].
[Nano medical particles] are so small that they cannot be seen by the naked eye.
Even with a microscope, [nano medical particles] can disguise themselves as small molecule compounds, which is impossible to distinguish with current human technology.
After [Additional Materials], the anti-cancer drug named [Redizumab] restarted a new round of experiments.
There is no need for He Youman to do these basic tasks.
The research team from [Xuanhu Technology] was transferred out to do this kind of [rough work]!
Because of my experience, I passed the first few levels easily. Animal experiments showed better experimental results, and then I came to clinical experiments.
This makes the research team of [Xuanhu Technology] very nervous.
This was where they failed last time.
Moreover, the number of people involved in this experiment was larger than the number of people involved in the clinical trials they conducted.
This is because [Chaoqun Group] attaches great importance to it, and Wu Siyuan attaches great importance to it.
The energy of [Super Group] is certainly not comparable to [Xuanhu Technology].